ReviewJournal of thrombosis and thrombolysis2001
Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease.
Review in Journal of thrombosis and thrombolysis, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 74 citations in OpenAlex.
- Trial
- Halo fluorescence fibrinolysis test: a novel quantitative assay to evaluate fibrinolysis on established plasma clots.Research and practice in thrombosis and haemostasis · 2025Article
- Plasminogen Activator Inhibitor-1 (Metabolites · 2021Article
- Plasminogen activator inhibitor-1: a potential etiological role in livedoid vasculopathy.International wound journal · 2020Review
- Effects of Weight Loss on Advanced Glycation End Products in Subjects with and without Diabetes: A Preliminary Report.International journal of environmental research and public health · 2017Article
- Plasminogen Activator Inhibitor-1 and Diagnosis of the Metabolic Syndrome in a West African Population.Journal of the American Heart Association · 2016Article
- Derangement of hemostasis in rheumatoid arthritis: association with demographic, inflammatory and metabolic factors.Clinical rheumatology · 2013Article
- Elevated plasminogen activator inhibitor type-1 (PAI-1) as contributing factor in pathogenesis of hypercoagulable state in antiphospholipid syndrome.Rheumatology international · 2013Article
- Remarkable stabilization of plasminogen activator inhibitor 1 in a "molecular sandwich" complex.Biochemistry · 2013Article
- Platelet glycoprotein IIIA PIA2 polymorphism is associated with ST elevation acute myocardial infarction in young Mexican population.Journal of thrombosis and thrombolysis · 2012Article
- The effect of secretory factors of adipose-derived stem cells on human keratinocytes.International journal of molecular sciences · 2012Article
- Plasminogen activator inhibitor-1 inhibits factor VIIa bound to tissue factor.Journal of thrombosis and haemostasis : JTH · 2011Article
- Plasminogen activator inhibitor-1 polymorphisms (-844 G>A and HindIII C>G) in systemic lupus erythematosus: association with clinical variables.Clinical and experimental medicine · 2011Article
- Article
- Impaired fibrinolysis in the antiphospholipid syndrome.Current rheumatology reports · 2010Review
- Plasminogen activator inhibitor-1 C/G polymorphism in relation to plasma levels in rheumatoid arthritis.Clinical and experimental medicine · 2009Article
- Key role of tissue plasminogen activator in neurovascular coupling.Proceedings of the National Academy of Sciences of the United States of America · 2008Article
- Thrombin-thrombomodulin inhibits prourokinase-mediated pleural mesothelial cell-dependent fibrinolysis.Thrombosis research · 2007Article
- PAI-1 and homocysteine, but not lipoprotein (a) and thrombophilic polymorphisms, are independently associated with the occurrence of major adverse cardiac events after successful coronary stenting.Heart (British Cardiac Society) · 2006Article
- Plasma fibrinolysis inhibitor levels in acute stroke patients with thrombolysis failure.Journal of clinical neurology (Seoul, Korea) · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasminogen activator inhibitor type-1 (PAI-1) is a rapid inhibitor of tissue plasminogen activator (tPA) in circulation. Evidence suggests that the PAI-1 concentration is responsible for the regulation of the endogenous fibrinolytic system through its tPA/PAI-1 interactions. Accordingly, increased levels of PAI-1 have emerged as a masker for an increased thrombolic risk. This article represents a status report of mechanism of action, regulation of plasma levels, as well as the role of PAI-1 in arterial and venous thromboembolic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.